This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on February 5, 2021
doi: 10.1158/2159-8290.CD-NB2021-0309
Sotorasib Edges Closer to Approval
Jump to section
Advertisement